Skip to main content
. 2014 Jan 8;2014(1):CD000031. doi: 10.1002/14651858.CD000031.pub4

Hall 2011.

Methods BUPROPION
Randomized controlled trial
Setting: Clinic, USA
Recruitment: community volunteers
Participants 406 smokers of ≥ 10 cpd
39% F, av age 41, av cpd 19, mean FTND 4.9
Interventions Relapse prevention study. All arms received same cessation intervention (5 sessions group counselling, 10wks NRT and 12wks bupropion at 150 mg/d for first 3 days and 300 mg/d for remainder). After cessation treatment ended:
1. Bupropion for 40wks (300mg/d)
2. As per 1, but placebo
3. As per 1, plus 11 sessions of individual CBT over 40 wks
4. As per 3, but placebo
5. No further treatment
Outcomes 7d PP at 2y
CO ≤ 10 ppm and urinary cotinine ≤ 60 ng/ml
Notes New for 2013 update.
Study report does not present absolute values for N abstinent, only adjusted ORs. N quit extrapolated from graph. Group 5 does not contribute to any analyses.
Funding: National Institute on Drug Abuse
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk “Randomly assigned,” methods not specified
Allocation concealment (selection bias) Unclear risk Not specified
Blinding (performance bias and detection bias) 
 All outcomes Unclear risk Participants blinded successfully but blinding of staff not reported
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk 83% followed up at 2y, similar rates across groups